Key Insights

Highlights

Treatment Research

2 treatments under study, led by Carvedilol

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 4 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

4Total
Phase 2 (4)

Trial Status

Active Not Recruiting4

Clinical Trials (4)

Showing 4 of 4 trials
NCT03775096Phase 2Active Not Recruiting

Adrenergic Blockers for Cardiac Changes in Early Parkinson's Disease (Protocol 53136)

NCT04218968Phase 2Active Not Recruiting

Cardiac Changes in Early Parkinson's Disease: A Follow up Study

NCT04386317Phase 2Active Not Recruiting

Terazosin Effect on Cardiac Changes in Early Parkinson's Disease

NCT05109364Phase 2Active Not RecruitingPrimary

Terazosin and Parkinson's Disease Extension Study

Showing all 4 trials

Research Network

Common Treatments

  • Carvedilol2
  • Terazosin2

Active Sponsors

  • Cedars-Sinai Medical Center3
  • Michele Tagliati, MD1

Top Investigators

Related Conditions

  • Rem Sleep Behavior Disorder4
  • Premotor Parkinsons Disease2
  • Premotor Parkinson Disease2

Activity Timeline